Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GEP signatures in tumors from women with high grade early breast cancer

ABSTRACT: Several molecular signatures are able to predict the activity of adjuvant chemotherapy in breast cancer patients. However, no molecular data are already available to detect microenvironment molecular signature that can identify patients who are good candidates for treatment with immune checkpoint inhibitors (ICIs). For this reason, in a series of women with operable high grade breast cancer (HGBC), we tried to combine the ECM3 and IFN molecular signatures reflecting different aspects of tumor microenvironment that can better draw the picture of the tumor microenvironment in which the immune cells are in close contact with extracellular matrix. Subgroup of G3 tumors extracted from the ECTO1 study (Gianni L. et al, JCO 2009)

ORGANISM(S): Homo sapiens

PROVIDER: GSE147472 | GEO | 2020/12/23

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

GEP signatures in tumors from women with high grade early breast cancer [PrimitiveTumor].

Project description:Several molecular signatures are able to predict the activity of adjuvant chemotherapy in breast cancer patients. However, no molecular data are already available to detect microenvironment molecular signature that can identify patients who are good candidates for treatment with immune checkpoint inhibitors (ICIs). For this reason, in a series of women with operable high grade breast cancer (HGBC), we tried to combine the ECM3 and IFN molecular signatures reflecting different aspects of tumor microenvironment that can better draw the picture of the tumor microenvironment in which the immune cells are in close contact with extracellular matrix. Grade 3 primary tumors

2020-12-23 | GSE147471 | GEO

GEP signatures of primary breast cells radiation treated.

Project description:GEP signatures of primary breast cells radiation treated.

| PRJNA435496 | ENA

GEP signatures of primary breast cells radiation treated.

Project description:Breast cancer (BC) recovery has considerably increased thanks to the advances achieved from research in this field. However, despite the important results obtained, BC remains a complex multifactorial disease with distinct subtypes associated with different outcomes.So, many efforts from radiobiological research are needed to help clinicians in understanding molecular features of a specific tumor subtype, in order to better define the most successful treatment plan, including the choice of the best Radiation Teraphy (RT) modality and schedule in clinical practice. The aim of the present study was to analyze the GEPs in primary breast cancer cells following irradiation with doses of 9 Gy and 23 Gy electron beam delivered by IOERT treatment, in order to define gene signatures of response to high doses of IR.

2021-02-19 | GSE110933 | GEO

Proteomic study on human breast cancer cells in response to different folate levels

Project description:The consequence of a supra-physiological folate tumour microenvironment in promoting metastasis potential of human breast cancers remains unexplored. This study examined the molecular mechanism by which clinically aberrant folate levels may promote mitochondria and glycolytic stress-associated proteomic signatures to promote metastasis potential of human MCF-7 breast cancer cells.

2022-11-21 | PXD011046 | Pride

Transcriptome profiling by array of normal fibroblasts and cancer associated fibroblasts (CAF) isolated from breast cancer skin metastasis, cutaneous basal cell carcinoma and squamous cell carcinoma arising from oral cavity mucous membrane

Project description:We focus on cancer-associated fibroblasts (CAFs) as an active component of the tumor microenvironment. The transcriptome profiling and analysis of CAFs isolated from breast cancer skin metastasis, cutaneous basal cell carcinoma and squamous cell carcinoma arising from oral cavity mucous membrane unravelled major gene candidates such as the IL-6, VEGF-A and MFGE8 that induced the expression of several markers associated with poor prognosis and epithelial-to-mesenchymal transition in co-cultivated EM-G3 breast cancer cells.

2023-10-02 | E-MTAB-12994 | biostudies-arrayexpress

T cells and monocyte-derived myeloid cells mediate immunotherapy-related hepatitis in a mouse model II

Project description:Immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs) which are more severe when ICIs are used in combination. A mouse model was developed to elucidate the molecular mechanisms of immune-related hepatitis, one of the common irAEs associated with ICIs. Molecular profiling by single cell RNA sequencing was performed on Pdcd1-/- mice treated with anti-CTLA4 and/or the IDO1 inhibitor epacadostat or a 4-1BB agonistic antibody. ICI combination-induced hepatitis and 4-1BB agonist-mediated hepatitis share similar features yet maintain distinct immune signatures. Both were characterized by an expansion of activated T cells. Single-cell transcriptomics revealed that the hepatitis induced by combination ICIs is associated with a robust immune activation signature in all subtypes of T cells and T helper 1 skewing. Expression profiling revealed a central role for IFNγ and liver monocyte-derived macrophages in promoting a pro-inflammatory T-cell response to ICI combination and 4-1BB agonism.

2022-11-16 | GSE218139 | GEO

T cells and monocyte-derived myeloid cells mediate immunotherapy-related hepatitis in a mouse model

2022-11-14 | GSE217917 | GEO

Two New Stromal Signatures Stratify Breast Cancers with Different Prognosis

Project description:Purpose: Multiple studies from last decades have shown that the microenvironment of carcinomas plays an important role in the initiation, progression and metastasis of cancer. Our group has previously identified novel cancer stroma gene expression signatures associated with outcome differences in breast cancer by gene expression profiling of two tumors of fibroblasts as surrogates for physiologic stromal expression patterns. The aim of this study is to find additional new types of tumor stroma gene expression patterns. Results: 53 tumors were sequenced by 3SEQ with an average of 29 million reads per sample. Both the elastofibroma (EF) and fibroma of tendon sheath (FOTS) gene signatures demonstrated robust outcome results for survival in the four breast cancer datasets. The EF signature positive breast cancers (20-33% of the cohort) demonstrated significantly better outcome for survival. In contrast, the FOTS signature positive breast cancers (11-35% of the cohort) had a worse outcome. The combined stromal signatures of EF, FOTS, and our previously identified DTF, and CSF1 signatures characterize, in part, the stromal expression profile for the tumor microenvironment for between 74%-90% of all breast cancers. Conclusions: We defined and validated two new stromal signatures in breast cancer (EF and FOTS), which are significantly associated with prognosis. Gene expression profiling by 3SEQ was performed on 8 additional types of fibrous tumors, to identify different fibrous tumor specific gene expression signatures. We then determined the significance of the fibrous tumor gene signatures in four publically available breast cancer datasets (GSE1456, GSE4922, GSE3494, NKI Dataset).

2013-11-21 | E-GEOD-42948 | biostudies-arrayexpress

GEP signatures in tumors from women with high grade early breast cancer

Project description:GEP signatures in tumors from women with high grade early breast cancer

| PRJNA614941 | ENA

medulloblastoma label free proteome analysis from an Indian subpopulation

Project description:The label free tissue proteomic analysis of medulloblastoma proteome was perfomed for the identification of protein markers for the developinment of IHC markers for the diagnostic purpose. The pathway al;tyerations and protein signatures of G3 tumor is the major focus.

2021-04-30 | PXD014950 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data